Advagraf

tacrolimus · Astellas Pharma Europe BV
AUTHORISED IN THE EU

What Advagraf is used for

Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Advagraf
Active substance
tacrolimus
Disease area
Graft Rejection
Medicine group
Immunosuppressants
ATC code
L04AD02
Marketing authorisation holder
Astellas Pharma Europe BV
Authorised in the EU since
2007

Official information

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Advagraf used for?

Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

What is the active substance in Advagraf?

Advagraf contains tacrolimus.

Who makes Advagraf?

The EU marketing authorisation holder is Astellas Pharma Europe BV.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.